Isoprinosine has been licensed since 1971 for the treatment of cell mediated immune deficiencies associated with various viral infections. It has been on the market for over 30 years and is currently registered in 43 countries world wide for a variety of indications. These include the treatment of HPV, HSV, VZV, CMV, EBV, measles virus infections and SSPE.
![]()
